Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPC3 | Q13507 | 1/20 | 0.54 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.54 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | CRACR2A | Q9BSW2 | 5/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1827030 | 0.90 | POLB (0.54) | TRPC3ORAI1TRPC5LMNAALDH1A1 | |
| SCHEMBL16363160 | 0.83 | LMNA (0.57) | TRPC3ORAI1TRPC5LMNAALDH1A1 | |
| SCHEMBL16363187 | 0.81 | LMNA (0.55) | TRPC3ORAI1TRPC5LMNAALDH1A1 | |
| SCHEMBL8297610 | 0.80 | POLB (0.55) | TRPC3ORAI1TRPC5LMNAALDH1A1 | |
| SCHEMBL16363166 | 0.80 | LMNA (0.54) | LMNAALDH1A1POLBGAAMEN1 | |
| SCHEMBL6621449 | 0.79 | LMNA (0.77) | TRPC3ORAI1TRPC5LMNAALDH1A1 | |
| SCHEMBL1826606 | 0.79 | IL2 (0.58) | TRPC3ORAI1TRPC5LMNAALDH1A1 | |
| SCHEMBL7972108 | 0.78 | LMNA (0.84) | TRPC3ORAI1TRPC5LMNAALDH1A1 | |
| SCHEMBL16363167 | 0.76 | GFER (0.53) | ALDH1A1CRACR2AGAAMEN1KMT2A | |
| SCHEMBL16363170 | 0.76 | TRPV1 (0.44) | LMNAAGTR1MEN1KMT2ATRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150005320-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2015-01-01 | — | — | US | disclosed |
| US-20140107134-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107134-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCR2, CXCL8, CCR9 | TRPC3 2002/4885ORAI1 1379/4885TRPC5 2164/4885 |
| US-20150005320-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCR2, CXCL8, CCR9 | TRPC3 2002/4885ORAI1 1379/4885TRPC5 2164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.